Search research articles
Contact Us
Filters
Showing results (51-60 of 69) with videos related to
Page
of 7
Sort By:
British Journal of Cancer
|
April 20, 2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer
A Sobrero, A Guglielmi, M Cirillo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
E Van Cutsem, K Muro, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H Bleiberg, G Decoster, A de Gramont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers
A Sobrero, A Zaniboni, G L Frassineti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
F Di Costanzo, A Sobrero, S Gasperoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E Van Cutsem, T Yoshino, H J Lenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
F Petrelli, E Rulli, R Labianca, et al.
British Journal of Cancer
|
March 18, 2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem, P M Hoff, P Harper, et al.
British Journal of Cancer
|
February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
C S Karapetis, H Liu, M J Sorich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 69) with videos related to
Sort By:
Page
of 7
British Journal of Cancer
|
April 20, 2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer
A Sobrero, A Guglielmi, M Cirillo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
E Van Cutsem, K Muro, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H Bleiberg, G Decoster, A de Gramont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers
A Sobrero, A Zaniboni, G L Frassineti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
F Di Costanzo, A Sobrero, S Gasperoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E Van Cutsem, T Yoshino, H J Lenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
F Petrelli, E Rulli, R Labianca, et al.
British Journal of Cancer
|
March 18, 2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem, P M Hoff, P Harper, et al.
British Journal of Cancer
|
February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
C S Karapetis, H Liu, M J Sorich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2016
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial
S Lonardi, A Sobrero, G Rosati, et al.
Page
of 7